129 related articles for article (PubMed ID: 25182961)
1. Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe.
Bogdanova N; Togo AV; Ratajska M; Kluźniak W; Takhirova Z; Tarp T; Prokofyeva D; Bermisheva M; Yanus GA; Gorodnova TV; Sokolenko AP; Kuźniacka A; Podolak A; Stukan M; Wokołorczyk D; Gronwald J; Vasilevska D; Rudaitis V; Runnebaum IB; Dürst M; Park-Simon TW; Hillemanns P; Antonenkova N; Khusnutdinova E; Limon J; Lubinski J; Cybulski C; Imyanitov E; Dörk T
Fam Cancer; 2015 Mar; 14(1):145-9. PubMed ID: 25182961
[TBL] [Abstract][Full Text] [Related]
2. A common nonsense mutation of the BLM gene and prostate cancer risk and survival.
Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM
Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176
[TBL] [Abstract][Full Text] [Related]
3. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations.
Prokofyeva D; Bogdanova N; Dubrowinskaja N; Bermisheva M; Takhirova Z; Antonenkova N; Turmanov N; Datsyuk I; Gantsev S; Christiansen H; Park-Simon TW; Hillemanns P; Khusnutdinova E; Dörk T
Breast Cancer Res Treat; 2013 Jan; 137(2):533-9. PubMed ID: 23225144
[TBL] [Abstract][Full Text] [Related]
4. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.
Sokolenko AP; Iyevleva AG; Preobrazhenskaya EV; Mitiushkina NV; Abysheva SN; Suspitsin EN; Kuligina ESh; Gorodnova TV; Pfeifer W; Togo AV; Turkevich EA; Ivantsov AO; Voskresenskiy DV; Dolmatov GD; Bit-Sava EM; Matsko DE; Semiglazov VF; Fichtner I; Larionov AA; Kuznetsov SG; Antoniou AC; Imyanitov EN
Int J Cancer; 2012 Jun; 130(12):2867-73. PubMed ID: 21815139
[TBL] [Abstract][Full Text] [Related]
5. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
[TBL] [Abstract][Full Text] [Related]
6. The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia.
Imyanitov E; Prokofyeva D; Bogdanova N; Dörk T
Breast Cancer Res Treat; 2014 Dec; 148(3):695-6. PubMed ID: 25410042
[No Abstract] [Full Text] [Related]
7. The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population.
Anisimenko MS; Kozyakov AE; Paul GA; Kovalenko SP
Breast Cancer Res Treat; 2014 Dec; 148(3):689-90. PubMed ID: 25399228
[No Abstract] [Full Text] [Related]
8. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
9. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 founder mutations compared to ovarian cancer in Belarus.
Savanevich A; Oszurek O; Lubiński J; Cybulski C; Dębniak T; Narod SA; Gronwald J
Fam Cancer; 2014 Sep; 13(3):445-7. PubMed ID: 24770866
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a RECQL splicing mutation, c.1667_1667+3delAGTA, in breast cancer patients and controls from Central Europe.
Bogdanova N; Pfeifer K; Schürmann P; Antonenkova N; Siggelkow W; Christiansen H; Hillemanns P; Park-Simon TW; Dörk T
Fam Cancer; 2017 Apr; 16(2):181-186. PubMed ID: 27832498
[TBL] [Abstract][Full Text] [Related]
12. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania.
Elsakov P; Kurtinaitis J; Petraitis S; Ostapenko V; Razumas M; Razumas T; Meskauskas R; Petrulis K; Luksite A; Lubiński J; Górski B; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):373-6. PubMed ID: 20345474
[TBL] [Abstract][Full Text] [Related]
13. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
[TBL] [Abstract][Full Text] [Related]
14. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer.
Bogdanova N; Cybulski C; Bermisheva M; Datsyuk I; Yamini P; Hillemanns P; Antonenkova NN; Khusnutdinova E; Lubinski J; Dörk T
Breast Cancer Res Treat; 2009 Nov; 118(1):207-11. PubMed ID: 18807267
[TBL] [Abstract][Full Text] [Related]
15. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
Sokolenko AP; Sokolova TN; Ni VI; Preobrazhenskaya EV; Iyevleva AG; Aleksakhina SN; Romanko AA; Bessonov AA; Gorodnova TV; Anisimova EI; Savonevich EL; Bizin IV; Stepanov IA; Krivorotko PV; Berlev IV; Belyaev AM; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2020 Nov; 184(1):229-235. PubMed ID: 32776218
[TBL] [Abstract][Full Text] [Related]
16. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
18. Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.
Krivokuca A; Dragos VS; Stamatovic L; Blatnik A; Boljevic I; Stegel V; Rakobradovic J; Skerl P; Jovandic S; Krajc M; Magic MB; Novakovic S
Fam Cancer; 2018 Apr; 17(2):179-185. PubMed ID: 28685474
[TBL] [Abstract][Full Text] [Related]
19.
Kim DH; Cho CH; Kwon SY; Ryoo NH; Jeon DS; Lee W; Ha JS
J Gynecol Oncol; 2018 Nov; 29(6):e90. PubMed ID: 30207098
[TBL] [Abstract][Full Text] [Related]
20. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
